Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRKDC | P78527 | 2/20 | 0.49 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.47 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.47 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.47 |
| ▸ | HPGD | P15428 | 2/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.44 |
| ▸ | TP53 | P04637 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.44 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.44 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.44 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.44 |
| ▸ | PIK3CA | P42336 | 3/20 | 0.44 |
| ▸ | PIK3CB | P42338 | 2/20 | 0.44 |
| ▸ | MTOR | P42345 | 2/20 | 0.44 |
| ▸ | PIK3CG | P48736 | 2/20 | 0.44 |
| ▸ | AKT1 | P31749 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1442648 | 0.91 | CYP1A2 (0.47) | PRKDCSLC6A4SLC6A3ALDH1A1TDP1 | |
| SCHEMBL12812446 | 0.90 | HPGD (0.49) | SLC6A2SLC6A4SLC6A3HPGDKDM4E | |
| SCHEMBL12811951 | 0.88 | HPGD (0.45) | PRKDCHPGDKDM4EALDH1A1CYP1A2 | |
| SCHEMBL1442982 | 0.86 | ATR (0.49) | PRKDCHPGDKDM4EALDH1A1TP53 | |
| SCHEMBL12812420 | 0.83 | PRKDC (0.52) | PRKDCHPGDTP53PIK3CAPIK3CB | |
| SCHEMBL1442713 | 0.82 | ALDH1A1 (0.61) | PRKDCHPGDKDM4EALDH1A1TDP1 | |
| SCHEMBL1442444 | 0.82 | PIK3CA (0.46) | PRKDCHPGDKDM4EALDH1A1PIK3CA | |
| SCHEMBL1442484 | 0.81 | HCRTR1 (0.43) | SLC6A2SLC6A4SLC6A3HPGDALDH1A1 | |
| SCHEMBL1442428 | 0.81 | ALDH1A1 (0.58) | PRKDCHPGDKDM4EALDH1A1TSHR | |
| SCHEMBL1442756 | 0.81 | MAPT (0.51) | PRKDCHPGDKDM4EALDH1A1TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9340528-B2 | Substituted aminoquinoxalines as tyrosine threonine kinase inhibitors | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2016-05-17 | — | — | US | claimed |
| US-20120263708-A1 | SUBSTITUTED AMINOQUINOXALINES AS TYROSINE THREONINE KINASE INHIBITORS | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2012-10-18 | — | — | US | claimed |
| CN-102596932-A | Substituted aminoquinoxalines as tyrosine threonine kinase inhibitors | BAYER SCHERING PHARMA AG | 2012-07-18 | — | — | CN | claimed |
| US-9340528-B2 | Substituted aminoquinoxalines as tyrosine threonine kinase inhibitors | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2016-05-17 | — | — | US | disclosed |
| US-9340528-B2 | Substituted aminoquinoxalines as tyrosine threonine kinase inhibitors | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2016-05-17 | — | — | US | disclosed |
| US-9340528-B2 | Substituted aminoquinoxalines as tyrosine threonine kinase inhibitors | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2016-05-17 | — | — | US | disclosed |
| US-20120263708-A1 | SUBSTITUTED AMINOQUINOXALINES AS TYROSINE THREONINE KINASE INHIBITORS | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2012-10-18 | — | — | US | disclosed |
| US-20120263708-A1 | SUBSTITUTED AMINOQUINOXALINES AS TYROSINE THREONINE KINASE INHIBITORS | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2012-10-18 | — | — | US | disclosed |
| WO-2011026579-A1 | SUBSTITUTED AMINOQUINOXALINES AS TYROSINE THREONINE KINASE INHIBITORS | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2011-03-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120263708-A1 | SUBSTITUTED AMINOQUINOXALINES AS TYROSINE THREONINE KINASE INHIBITORS | ABL1, TYK2, JAK2 | PRKDC 111/4885SLC6A2 3056/4885SLC6A4 2927/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.